About ONCHILLES PHARMA, INC
Onchilles Pharma is a global drug discovery and development company pioneering first-in-class cytotoxic therapies that selectively kill cancer cells while preserving and activating immune function. The company is advancing its lead programs, N17350 (NEU-001) and NEU-002, toward clinical trials with first-in-human studies anticipated in 2026.
Development of first-in-class cytotoxic therapies targeting the ELANE pathwayDesign of tumor-directed cytotoxic agents for intratumoral and intravenous deliveryPreclinical validation across 11 cancer types, 80 cell lines, and 25 animal modelsInduction of immunogenic cancer cell death while preserving immune function
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ONCHILLES PHARMA, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.